Lucid promotes new guideline from ACG on esophageal cancer

By staff writers

April 4, 2022 -- Diagnostics developer Lucid Diagnostics is highlighting updated clinical guidelines for esophageal cancer screening published in the April issue of the American Journal of Gastroenterology.

The new guidelines include a reference to screening for esophageal cancer using Lucid's EsoGuard DNA test on samples collected with its EsoCheck Cell Collection device, it said.

A draft of local coverage determination for molecular testing for esophageal cancer has been published on the U.S. Centers for Medicare and Medicaid Services' (CMS) website, the company said. It refers to Medicare administrative contractor Palmetto GBA's Molecular Diagnostic Services (MolDX) program, which is part of Lucid's efforts to secure Medicare coverage for EsoGuard, according to the firm.

This local coverage determination document prompts a comment period until May 14, Lucid said.

1st patient enrolled in study for Lucid's EsoGaurd test
Lucid Diagnostics said the first patient has been enrolled in a study of the company's EsoGuard Esophageal DNA Test at the Louis Stokes Cleveland Department...
Lucid launches 3 new test centers
Lucid Diagnostics, a Pavmed subsidiary, has launched Lucid Test Centers in Seattle, Portland, and Boise, ID. After physician referrals, patients can get...
Lucid closes Nasdaq initial public offering
The cancer prevention medical diagnostics firm Lucid Diagnostics, a subsidiary of PAVmed, has closed its initial public offering.
Lucid Diagnostics files for IPO on Nasdaq exchange
Lucid Diagnostics has filed for an initial public offering (IPO), and the company's shares will be traded on the Nasdaq stock exchange under the symbol...
Lucid launches EsoGuard pilot test at centers in Ariz.
Lucid Diagnostics has launched three test centers in Phoenix, where patients are undergoing esophageal precancer testing in a pilot test of the company's...

Copyright © 2022

Last Updated 4/5/2022 6:13:18 AM